What's new? Log in Free sign up

Filing search / Kineta, Inc. / "Offset"

Search information

Kineta, Inc.

Companies

"Offset"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

97 results

Newest first Best match first

KANT Kineta, Inc.

Quarterly report

candidate, and ALS program expenses incurred to complete project services in 2023 under the Merck Neuromuscular License Agreement, partially offset … and decreased by $2.1 million, or 28%. This decrease was primarily due to a decrease in personnel costs of $2.3 million, partially offset by an increase

8 Aug 24

4:00pm

KANT Kineta, Inc.

Quarterly report

of $132,000 was primarily due to higher activities for KVA12123, our lead product candidate, and licensing costs for CD27, partially offset by lower … in personnel costs of $538,000 and other administrative expenses of $328,000, partially offset by an increase in professional services of $441,000

15 May 24

4:05pm

KANT Kineta, Inc.

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

space, partially offset by higher activities for KVA12123, our lead product candidate, and CD27 licensing expense. General and administrative expense … , 2023. The decrease was primarily due to a decrease in personnel costs of $538,000 and other administrative expenses of $328,000, partially offset

KANT Kineta, Inc.

Definitive proxy

engaging in any transactions that hedge or offset any decrease in the market value of the Company’s securities or limit the ability to profit from

26 Apr 24

4:00pm

KANT Kineta, Inc.

, the carrying value of certain of Kineta’s deferred tax assets would decrease. Moreover, Kineta’s ability to use its NOL and other deferred tax assets to offset … to generate revenue from acquired intellectual property, technology and/or products sufficient to meet Kineta’s objectives or even to offset the associated

21 Mar 24

4:06pm

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

tjpsgixfx 3j92d3n

Quarterly report

3 Nov 23

4:04pm

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Quarterly report

11 Aug 23

4:07pm

Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Quarterly report

11 May 23

5:22pm

Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update

cdjtyj0u1ef gd1f6

Definitive proxy

28 Apr 23

5:09pm

31 Mar 23

4:05pm

nl5t8d074t neawd9

Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update

Kineta Completes Reverse Merger with Yumanity Therapeutics

Kineta Completes Reverse Merger with Yumanity Therapeutics

Business combination disclosure

8f54bxulmnictfj

Quarterly report

14 Nov 22

8:44am

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Prev
1
2
3
4
5
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.